Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Inclusion Criteria * Women must be of non childbearing status * Understands the study procedures in the ICF and be willing and able to comply with the protocol. * Willingness and ability to swallow study drug capsule. * Adult men or women, 18 to 75 years of age Hepatic-Impaired Subjects Only: * Subject has a diagnosis of chronic, stable HI. * Subject's score on the Child-Pugh scale must range from 10 to 15 at screening. Exclusion Criteria * History or presence of clinically significant or unstable medical or psychiatric condition or disease in the opinion of the PI. * Dosed in another clinical trial within 28 days before dosing of study drug and throughout the current study. * History or presence of drug abuse within 2 years before screening.